Evidence guide · US
Epitalon: the 'telomere peptide', the small human studies and the safety gaps
Epitalon is one of six peptides in the October 2026 US compounding policy. What the cell, mouse and small human studies show, what the FDA found on safety, and why the telomere claims run ahead of the evidence.
Review type: research summary. This page summarises published research and product labels, cited below.
Epitalon, also spelled epithalon and sometimes called AEDG after its four amino acids (alanine, glutamic acid, aspartic acid and glycine), is one of the six peptides named in the US Department of Health and Human Services (HHS) compounding policy announced in the Federal Register on October 30, 2026, alongside BPC-157, KPV, MOTS-c, Semax and TB-500. Clinics and online sellers promote it as an anti-aging peptide that switches on telomerase, the enzyme that rebuilds the protective caps on the ends of chromosomes. A US Food and Drug Administration (FDA) briefing for a July 2026 advisory meeting notes websites saying it is often referred to as "the fountain of youth".
Short answer: epitalon has measurable effects on cells and laboratory animals, but the case for it in people rests on a handful of small studies, many from one research network in St Petersburg and Kyiv. No adequately powered randomized trial has shown that it improves health or slows aging in people, and the human studies of epitalon summarized in a 2026 review in the International Journal of Molecular Sciences measured melatonin markers, clock genes and eye function, not telomere length. The FDA found no human pharmacokinetic data and no clinical studies assessing its safety, and its staff flagged a theoretical cancer concern because of the telomerase effect. That review sums epitalon up as biologically active but clinically unproven.
What epitalon is
Epitalon is a synthetic tetrapeptide designed from the amino acid make-up of epithalamin, a polypeptide extract of the pineal gland, the small gland in the brain that makes melatonin. The two are not the same thing. The FDA considers epitalon and epithalamin different substances, and the 2026 review treats the epithalamin studies only as historical context, because an extract of many peptides cannot stand in for one defined molecule. Much of the longevity research cited for epitalon was done with epithalamin, a different preparation.
Much of the research comes from Vladimir Khavinson's group at the St Petersburg Institute of Bioregulation and Gerontology and from collaborators at the Institute of Gerontology in Kyiv. The 2026 review notes that much of the epitalon literature comes from a limited number of investigators, and that some of the human reports appear to describe overlapping groups of patients rather than separate studies.
What the evidence says
Grades used here: Strong (consistent results from several good-quality human trials), Moderate (good trials, but few or with mixed results), Limited (small or low-quality human studies), Insufficient (too little human research to judge) and Evidence of harm. Animal and cell studies do not count toward a grade.
Telomeres and aging: Insufficient
A 2003 study from the Khavinson group reported that adding epitalon to cultured human fetal fibroblasts that lacked telomerase switched on the enzyme and lengthened telomeres. A 2025 study from Brunel University London, by researchers outside that network, reported dose-dependent telomere lengthening in normal human epithelial cells and fibroblasts through telomerase, and in two breast cancer cell lines through a different route called alternative lengthening of telomeres. A correction published in November 2025 replaced the paper's first three figures, and the 2026 review advises caution in interpreting its telomerase findings. None of these studies measured telomeres in a person taking epitalon.
The best-known animal study gave female outbred mice (54 per group) 1 microgram of epitalon by injection on five days every month from the age of three months until death. Mean lifespan did not change. The authors reported a 13.3% longer lifespan in the last 10% of survivors, a 12.3% longer maximum lifespan, fewer chromosome aberrations in bone marrow cells and less leukemia, with no change in total tumor incidence. The FDA's review points out that this schedule meant at most about 22 weeks of actual exposure, in female mice only, at a single dose.
Sleep and melatonin: Insufficient
Insomnia was the use the FDA evaluated in 2026, yet it found no published study of epitalon in people with insomnia. The closest is a randomized, placebo-controlled study of 40 women aged 40 to 50, mostly night-shift workers, whose urinary levels of a melatonin breakdown product were low. Half used a sublingual epitalon spray (0.5 mg a day) for 20 days and half used a salt-water spray. The marker rose 1.7-fold on epitalon and did not change on placebo. The FDA notes that the paper did not specify blinding, did not measure sleep and was short and small. A related report in a closely overlapping group of women looked at circadian clock genes in blood cells, and an older study in 15 elderly people given epitalon injections reported higher nighttime melatonin mainly in those whose pineal function was low to begin with.
Eyes: Insufficient
A 2002 report from the Khavinson group described epitalon injections around the eye in people with retinitis pigmentosa, an inherited condition that damages the retina, with a positive clinical effect in 90% of cases. The 2026 review notes that randomization and blinding were unclear and that the comparison group received conventional treatment rather than a placebo. Epitalon received a US orphan drug designation for retinitis pigmentosa in September 2010, which was withdrawn or revoked in January 2016, according to the FDA briefing.
The epithalamin mortality studies
The claims that these peptides extend human life come from epithalamin, not epitalon. A 2003 report on 266 older people followed for six to eight years described 1.6 to 1.8 times lower mortality in the epithalamin group than in controls, alongside groups given a thymus extract. A study in 70 elderly people with coronary disease, described by its authors as randomized (36 given epithalamin, 34 controls), reported 28% fewer deaths after 12 years. The 2026 review calls this evidence methodologically limited, notes that blinding was not clearly described, and says it cannot be extrapolated to epitalon.
Safety in people: Insufficient
The FDA briefing for its Pharmacy Compounding Advisory Committee, dated May 12, 2026, found no pharmacokinetic data for epitalon in people and no clinical studies assessing its safety. Searches of the FDA's drug adverse event database (to December 8, 2025) and its foods and supplements complaint system (to December 5, 2025) found no reports. For the drug database, the FDA notes that reporting is voluntary, that it does not receive all adverse event reports, especially for compounded products, and that it cannot draw definitive safety conclusions from those data alone. It raised three concerns:
- Cancer risk is unknown. Because epitalon has been reported to activate telomerase and lengthen telomeres, the FDA says continuous exposure through life could in theory help cells evade senescence and become cancerous, and it found no two-year carcinogenicity studies. The mouse studies did not show more tumors, but the FDA judged them too limited in scope and duration to settle the question.
- Immune reactions. Injected peptides can trigger immune responses, a risk the FDA says may be raised by aggregation and peptide-related impurities. It found no clinical studies of epitalon's immunogenicity.
- Quality. The FDA judged neither epitalon nor its acetate salt well characterized, citing naming that does not follow standard chemical conventions and missing or inadequate quality data for an injection, including tests for peptide impurities, aggregates and microbial contamination.
Products sold online are a further unknown. The FDA found 10 mg, 20 mg, 25 mg and 50 mg vials, 3 mg and 3.3 mg capsules and an oral spray for sale, several labeled for research use only. A 2015 study by Belgium's public health institute identified epitalon in two illegal pharmaceutical preparations; the 2026 review notes that confirming the molecule's identity says nothing about purity, dose accuracy or sterility.
Where it stands with US regulators
Epitalon is not an FDA-approved drug and is not part of any approved product. FDA staff concluded that the evidence weighed against adding epitalon or epitalon acetate to the list of substances pharmacies may use for compounding under section 503A, citing poor characterization, no human safety data, immunogenicity concerns and no evidence of effectiveness for insomnia. At the advisory committee meeting on July 24, 2026, the committee recommended inclusion anyway, by a narrow vote. That recommendation is advisory and does not make epitalon approved, safe or effective. On the FDA page about bulk substances that may present significant safety risks in compounding, epitalon appears under nominations that were withdrawn, not in the current category 2 table; that entry says the agency lacks sufficient information to know whether the drug would cause harm if given to people.
Our view
- Epitalon has effects in cells and mice, but that is a long way from showing it slows aging in people. The human studies of epitalon summarized in the 2026 review did not measure telomere length.
- The human studies are small, short, mostly from one research network, and measured markers such as melatonin rather than health outcomes. The life-extension figures come from epithalamin, a different substance.
- The FDA found no human safety studies and flagged a theoretical cancer concern linked to telomerase activation with long-term exposure. That is a reason for caution with a product that some sellers recommend taking in repeated cycles.
- Do not inject epitalon bought online. Identifying the peptide does not establish the purity, dose or sterility of products sold online.
- If you are interested in healthy aging or better sleep, talk to your doctor about approaches with human evidence, and ask about clinical trials rather than self-sourcing peptides.
US rules
On October 30, 2026, the Federal Register announced an interim HHS policy: until FDA rulemaking decides whether each of the six peptides belongs on the 503A bulks list, HHS does not intend to take enforcement action against a state-licensed pharmacy, federal facility or licensed physician compounding a drug product with one of them, under the conditions in the policy. It is not an approval. Compounded drugs are not FDA-approved, which means FDA does not review their safety, effectiveness or quality before they are marketed, and HHS says it may revisit the policy if a safety signal or product quality issue arises. The policy covers compounding for individual patients, not "research use only" vials sold online. Talk to your doctor before using any peptide, and report a suspected side effect from a drug through FDA's MedWatch program.
FAQ
Is epitalon a supplement?
No. It is an unapproved peptide drug substance. The FDA found it for sale as vials, capsules and an oral spray. The FDA found no approved epitalon product in the US, Canada, Australia or the UK, and none authorized for use in the European Union by the European Medicines Agency.
Does epitalon lengthen telomeres?
In cultured human cells, two studies report that it does, and one of them has since been corrected. The human studies of epitalon summarized in the 2026 review did not measure telomere length, so whether it does anything to telomeres in the body is unknown.
Is epitalon the same as epithalamin?
No. Epithalamin is an extract of many peptides from the pineal gland; epitalon is one synthetic four-amino-acid peptide designed from it. The FDA treats them as different substances, so results from epithalamin studies do not transfer to epitalon.
Will epitalon help me sleep?
There is no study of epitalon in people with insomnia. Small studies reported higher melatonin markers in women and older people whose levels were low, but none measured sleep.
Sources
These are the documents this page relies on.
- Jain A, Gallacher DM, Issa MA, et al. Epitalon and epithalamin: a narrative review of mechanistic, preclinical, and clinical evidence. Int J Mol Sci. 2026;27(19):8922International Journal of Molecular Sciences (PubMed 42884164, PMC13664938)
- FDA Briefing Document: FDA evaluation of epitalon-related bulk drug substances (epitalon (free base) and epitalon acetate), Pharmacy Compounding Advisory Committee meeting, July 23 and 24, 2026US Food and Drug Administration
- July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory CommitteeUS Food and Drug Administration
- Anisimov VN, Khavinson VKh, Popovich IG, et al. Effect of Epitalon on biomarkers of aging, life span and spontaneous tumor incidence in female Swiss-derived SHR mice. Biogerontology. 2003;4(4):193-202Biogerontology (PubMed 14501183)
- Khavinson VKh, Bondarev IE, Butyugov AA. Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells. Bull Exp Biol Med. 2003;135(6):590-592Bulletin of Experimental Biology and Medicine (PubMed 12937682)
- Al-Dulaimi S, Thomas R, Matta S, Roberts T. Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity. Biogerontology. 2025;26(5):178, with correction in Biogerontology. 2025;27(1):1Biogerontology (PubMed 40908429 and 41240216)
- Khavinson VKh, Morozov VG. Peptides of pineal gland and thymus prolong human life. Neuro Endocrinol Lett. 2003;24(3-4):233-240Neuro Endocrinology Letters (PubMed 14523363)
- Korkushko OV, Khavinson VKh, Shatilo VB, Antonyuk-Shcheglova IA. Geroprotective effect of epithalamine (pineal gland peptide preparation) in elderly subjects with accelerated aging. Bull Exp Biol Med. 2006;142(3):356-359Bulletin of Experimental Biology and Medicine (PubMed 17426848)
- Khavinson V, Razumovsky M, Trofimova S, Grigorian R, Razumovskaya A. Pineal-regulating tetrapeptide epitalon improves eye retina condition in retinitis pigmentosa. Neuro Endocrinol Lett. 2002;23(4):365-368Neuro Endocrinology Letters (PubMed 12195242)
- Vanhee C, Moens G, Van Hoeck E, Deconinck E, De Beer JO. Identification of the small research tetra peptide Epitalon, assumed to be a potential treatment for cancer, old age and retinitis pigmentosa in two illegal pharmaceutical preparations. Drug Test Anal. 2015;7(3):259-264Drug Testing and Analysis (PubMed 25535022)
- HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendices A and B (October 2026)US Department of Health and Human Services
- Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances. Notice of availability, Docket HHS-OASH-2026-0496. Federal Register 91(209):68526-68527, October 30, 2026Federal Register (GovInfo)
- Category 2 of the bulk substances nominated under sections 503A or 503B of the Federal Food, Drug, and Cosmetic Act (content current as of April 22, 2026)US Food and Drug Administration
- MedWatch: the FDA safety information and adverse event reporting programUS Food and Drug Administration